Immunotherapy with IL-10- and IFN-γ-producing CD4 effector cells modulate "natural" and "inducible" CD4 TReg cell subpopulation levels: Observations in four cases of patients with ovarian cancer

Cancer Immunology, Immunotherapy

Volumn 61, Issue 6, 2012, Pages 839-854

  Dobrzanski, Mark J ^a,b   Rewers Felkins, Kathleen A ^a   Samad, Khaliquzzaman A ^a   Quinlin, Imelda S ^a   Phillips, Catherine A ^a,c   Robinson, William ^a,d   Dobrzanski, David J ^b   Wright, Stephen E ^a,c  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b Bristol Hospital   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d Harrington Cancer Center   (United States)

Author keywords

Adoptive T cell immunotherapy; IFN ; IL 10; Recurrent ovarian cancer; Regulatory T cells; T effector memory cells; Th1 effector cells; TNF superfamily; Tumor immunity

Indexed keywords

CARBOPLATIN; CISPLATIN; GAMMA INTERFERON; GEMCITABINE; INTERLEUKIN 10; INTERLEUKIN 2; MUCIN 1; PACLITAXEL; TUMOR NECROSIS FACTOR;

ADOPTIVE IMMUNOTHERAPY; ADULT; AGED; APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; CASE REPORT; CD3+ CD4+ CD25+ T LYMPHOCYTE; CD3+ CD4+ CD25- T LYMPHOCYTE; CD4+ CD25+ CD45RO+ FOXP3+ REGULATORY T LYMPHOCYTE; CD4+ CD25- FOXP3- IL 10+ REGULATORY T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL LINE; CELL SURVIVAL; CELLULAR IMMUNITY; DISEASE FREE SURVIVAL; EFFECTOR CELL; EX VIVO STUDY; FEMALE; HUMAN; INFUSION; MEMORY CELL; MEMORY T LYMPHOCYTE; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; RECURRENT CANCER; REGULATORY T LYMPHOCYTE; SURVIVAL TIME; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TUMOR IMMUNITY;

AGED; FEMALE; HUMANS; IMMUNOTHERAPY; INTERFERON-GAMMA; INTERLEUKIN-10; MIDDLE AGED; MUCIN-1; OVARIAN NEOPLASMS; PHENOTYPE; T-LYMPHOCYTES, REGULATORY;

EID: 84862330575     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-011-1128-x     Document Type: Article

References (79)

1. Jemel A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics. CA Cancer J Clin 59:225-249
2. Yap T, Carden CP, Kaye SB (2009) Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer 9:167-181
3. Nelson BH (2008) The impact of T cell immunity on ovarian cancer outcomes. Immunol Rev 222:101-116
4. + T cells. Curr Opin Immunol 21:200-208
5. O'Garra A, Vieira P (2007) Th1 cells control themselves by producing IL-10. Nat Rev Immunol 7:425-428 (Pubitemid 46834852)
6. Trinchieri G (2007) IL-10 production by effector T cells: Th1 cells show self control. J Exp Med 204:239-243
7. Jankovic D, Kugler DG, Sher A (2010) IL-10 production by CD4 effector T cells: a mechanism for self regulation. Mucosal Immunol 3:239-246
8. Haringer B, Lozza L, Steckel B, Geginat J (2009) Identification and characterization of IL-10/IFN-γ-producing effector-like T cells with regulatory function in human blood. J Exp Med 206:1009-1017
9. Gerosa F, Nisii C, Righetti S, Micciolo R, Marchesini M, Cazzadori A, Trinchieri G (1999) CD4 T cell clones producing both IFN-γ and IL-10 predominate in bronchoalveolar lavages of active pulmonary tuberculosis patients. Clin Immunol 92:224-234 (Pubitemid 29439669)
10. + T cell help in cancer immunity and the formation of novel cancer vaccines. Cancer Immunol Immunther 56:70-80
11. Kennedy R, Celis E (2008) Multiple roles of CD4 T cells in antitumor responses. Immunological Revs 222:129-144 (Pubitemid 351430378)
12. Newsbeth YC, Martinez DG, Toraya S, Scarlett UK, Cubillos-Ruiz JR, Rutkowski MR, Conejo-Garcia JR (2010) CD4 T cells elicit host immune responses to MHC Class II-ovarian cancer through CCL5 secretion and CD40 mediated licensing of dendritic cells. J Immunol 184:5654-5662
13. Perez-Diez A, Joncker NT, Choi K, Chan WFN, Anderson CC, Lantz O, Matzinger P (2007) CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood 109:5346-5354 (Pubitemid 46890556)
14. Moeller M, Haynes NM, Kershaw MH, Jackson JT, Teng MWL, Street SE, Cerutti L, Jane SM, Trapani JA, Smyth MJ, Darcy PK (2005) Adoptive transfer of gene-engineered CD4 helper T cells induce potent primary and secondary tumor rejection. Blood 106:2995-3003 (Pubitemid 41565891)
15. Liu Z, Noe HS, Chen J, Kim JH, Falo LD Jr, You Z (2008) Potent tumor-specific protection ignited by adoptively transferred CD4 T cells. J Immunol 181:4363-4370
16. Nesbeth Y, Conejo-Garcia JR (2010) Harnessing the effects of adoptively transferred tumor-reactive T cells on endogenous antitumor responses. Clinical Developmental Immunol. doi: 10.155/2010/13904
17. Hunder NN, Wallen H, Cao J, Hendricks DW, Reilly JZ, Rodmyre R, Jungbluth A, Gnjatic S, Thompson JA, Yee C (2008) Treatment of metastatic melanoma with autologous CD4 T cells against NY-ESO-1. N Eng J Med 358:2698-2703 (Pubitemid 351860862)
18. Nishikawa H, Sakaguchi S (2010) Regulatory T cells in tumor immunity. Int J Cancer 127:759-767
19. + regulatory T cells in the human immune system. Nat Revs Immunol 10:490-500
20. Sakaguchi S (2008) Regulatory T cells and immune tolerance. Cell 133:775-787
21. Riley JL, June CH, Blazer BR (2009) Human T regulatory cell therapy: take a billion or so and call me in the morning. Immunity 30:656-665
22. + regulatory T cells in human autoimmune disease. Nat Rev Immunol 10:849-859
23. + T regulatory cell-mediated suppression. Immunity 30:636-645
24. + regulatory T cells: their knowns and unknowns. Immunol Cell Biol 89:346-351
25. Grazia Roncarolo M, Gregori S, Battaglia M, Bacchetta R, Fleischhauer K, Levings MK (2006) IL-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev 212:28-50 (Pubitemid 44116698)
26. + T cell subset inhibits antigen-specific T cell responses and prevents colitis. Nature 389:737-742
27. O'Garra A, Vieira PL, Vieira P, Goldfeld AE (2004) IL-10 producing and naturally occurring CD4 Tregs: limiting collateral damage. J Clin Invest 114:1372-1378 (Pubitemid 40385564)
28. Zou W (2006) Regulatory T cells, tumor immunity and immunotherapy. Nat Rev Immunol 6:295-307
29. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burrow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Luckner A, Disis ML, Knutson KL, Chen W, Zou W (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942-949 (Pubitemid 39273735)
30. Wolf D, Wolf AM, Rumpold H, Fiegl H, Zeimet AG, Muller-Holzner E, Deibl M, Gastl G, Gunsilius E, Marth C (2005) The expression of the regulatory T Cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res 11:5380-8326
31. Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, Coukos G, Rubin SC, Kaiser LR, June CH (2001) CD4/CD25 + T cells in tumors from patients with early-stage non-small lung cancer and late stage ovarian cancer. Can Res 61:4766-4772 (Pubitemid 32691889)
32. Dobrzanski MJ, Rewers-Felkins KA, Abdul Samad K, Quinlin IS, Robinson W, Dobrzanski DJ, Wright SE (2009) Autologous MUC1-specific Th1 effector cell immunotherapy induces differential levels of systemic TReg cell populations that result in increased ovarian cancer patient survival. Clin Immunol 133:333-352
33. Wright SE, Rewers-Felkins KA, Quinlin IS, Eldridge PW, Zorsky PE, Klug P, Phillips CA (2002) Adoptive immunotherapy of mucin1 expressing adenocarcinomas with mucin1 stimulated human peripheral blood mononuclear cells. Int J Mol Med 9:401-404
34. Wright SE, Khaznadar R, Wang Z, Quinlin IS, Rewers-Felkins KA, Phillips CA, Patel S (2008) Generation of MUC1-stimulated mononuclear cells using optimized conditions. Scand J Immunol 67:24-29 (Pubitemid 350209581)
35. Hiltbold EM, Ciborowski P, Finn OJ (1998) Naturally processed class II epitope from the tumor antigen MUC1 primes human CD4 T cells. Can Res 58:5066-5070 (Pubitemid 28521162)
36. Dobrzanski MJ, Reome JB, Hylind JC, Rewers-Felkins KL (2006) CD8-mediated type 1 antitumor responses selectively modulate endogenous differentiated and non-differentiated T cell localization, activation and function in progressive breast cancer. J Immunol 177:8191-8201 (Pubitemid 44846340)
37. Croft M (2009) The role of TNF superfamily members in T cell function and diseases. Nat Rev Immunol 9:271-285
38. O'Garra A, Barrat RJ, Castro AG, Vicari A, Hawrylowicz C (2008) Strategies for use of IL-10 or its antagonists in human disease. Immunol Rev 223:114-131 (Pubitemid 351986180)
39. Saraiva M, O'Garra A (2010) The regulation of IL-10 production by immune cells. Nat Rev Immunol 10:170-181
40. Murai M, Turovskaya O, Kim G, Madan R, Karp CL, Cheroutre H, Kronenberg M (2009) IL-10 acts on regulatory T cells to maintain expression of the transcription factor FoxP3 and suppress function in mice with colitis. Nat Immunol 10:1178-1184
41. Pierson W, Liston A (2010) A new role for IL-10 in immune regulation. Immunol Cell Biol 88:769-770
42. Jarnicki AG, Lysaght J, Todryk S, Mills KHG (2006) Suppression of antitumor immunity by IL-10 and TGF-β -producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells. J Immunol 177:896-904 (Pubitemid 44036590)
43. Tilg H, van Montfrans C, van den Ende A, Kaser A, van Deventer SJ, Schreiber S, Gregor M, Ludwiczek O, Rutgeerts P, Gasche C, Koningsberger JC, Abreu L, Kuhn I, Cohard M, LeBeaut A, Grint P, Weiss G (2002) Treatment of Crohn's disease with recombinant human IL-10 induces the proinflamatory cytokine IFN-γ. Gut 50:191-195 (Pubitemid 34087930)
44. Lauw FN, Pajkrt D, Hack CE, Kurimoto M, van Deventer SJ, van der Poll T (2000) Proinflammatory effects of IL-10 during human endotoxemia. J Immunol 165:2783-2789 (Pubitemid 30660729)
45. Chen WF, Zlotnik A (1991) IL-10: a novel cytotoxic T cell differentiation factor. J Immunol 147:528-534
46. Groux H, Bigler M, de Vries JE, Roncarolo MG (1998) Inhibitory and stimulatory effects of IL-10 on human CD8 T cells. J Immunol 160:3188-3193 (Pubitemid 28164707)
47. Mocellin S, Marincola FM, Young HA (2005) Interleukin-10 and the immune response against cancer: a counterpoint. J Leukoc Biol 78:1043-1051 (Pubitemid 41572467)
48. Zheng LM, Ojcius DM, Garaud F, Roth C, Maxwell E, Li Z, Rong H, Chen J, Wang XY, Catino JJ, King I (1996) IL-10 inhibits tumor metastasis through an NK cell-dependent mechanism. J Exp Med 184:579-584 (Pubitemid 26324111)
49. Berman RM, Suzuki T, Tahara H, Robbins PD, Narula SK, Lotze MT (1996) Systemic administration of cellular IL-10 induces an effective specific and long lived immune response against established tumors in mice. J Immunol 157:231-238 (Pubitemid 26190552)
50. Fujii S, Shimizu K, Shimizu T, Lotze MT (2001) IL-10 promotes the maintenance of antitumor CD8 T effector cell function in situ. Blood 98:2143-2151
51. Dobrzanski MJ, Reome JB, Hylind JC, Rewers-Felkins KA, Abdulsamad K, Adams SL (2008) Ag-specific type 1 CD8 effector cells enhance methotrexate-mediated antitumor responses by modulating endogenous CD49b-expressing CD4 and CD8 T effector cell subpopulations producing IL-10. Immunol Invest 37:315-338 (Pubitemid 351892614)
52. Jones M, Ladell K, Wynn KK, Stacey MA, Quiqley MF, Gostick E, Price DA, Humphreys IR (2010) IL-10 restricts memory T cell inflation during cytomegalovirus infection. J Immunol 185:3583-3592
53. Kang SS, Allen PM (2005) Priming in the presence of IL-10 results in direct enhancement of CD8 T cell primary responses and inhibition of secondary responses. J Immunol 174:5382-5389 (Pubitemid 40593177)
54. Foulds KE, Rotte MJ, Seder RA (2006) IL-10 is required for optimal CD8 T cell memory following Listeria monocytogenes infection. J Immunol 177:2565-2574 (Pubitemid 44201015)
55. Dunn GP, Koebel CM, Schreiber RD (2006) Interferons, immunity and cancer immunoediting. Nat Rev Immunol 6:836-848 (Pubitemid 44631652)
56. + regulatory T cells in antitumor immune response. J Immunol 175:4433-4440
57. + Tregs. J Clin Invest 116:2434-2441
58. Cao X, Leonard K, Collins LI, Cai SF, Mayer JC, Peyton JE, Walter MJ, Piwnica-Worms D, Schreiber RD, Ley TJ (2009) IL-12 stimulates IFN-g-mediated inhibition of tumor-induced regulatory T cell proliferation and enhances tumor clearance. Can Res 69:8700-8709
59. + regulatory T cells are derived by rapid turnover of memory populations in vivo. J Clin Invest 116:2423-2433
60. Komatsu N, Mariotti-Ferrandiz ME, Wang Y, Malissen B, Waldmann H, Hori S (2009) Heterogeneity of natural FoxP3 T cells: a committed regulatory T cell lineage and an uncommitted minor population retaining plasticity. PNAS 106:1903-1908
61. Hendriks J, Gravestein LA, Tesselaar K, van Lier RA, Schumacher TN, Borst J (2000) CD27 is required for generation and long-term maintenance of T cell immunity. Nat Immunol 1:433-440
62. Hendriks J, Xiao Y, Borst J (2003) CD27 promotes survival of activated T cells and complements CD28 in generation and establishment of the effector T cell pool. J Exp Med 198:1369-1380 (Pubitemid 37392482)
63. Ramon-Arens R, Schepers K, Nolte MA, van Oosterwijk MF, van Lier RAW, Schumacher TNM, van Oers MHJ (2004) Tumor rejection induced by CD70-mediated quantitative and qualitative effects on effector CD8 T cell formation. J Exp Med 199:1595-1605 (Pubitemid 38780414)
64. Valzasina B, Guiducci C, Dislich H, Killeen N, Weinberg AD, Colombo MP (2005) Triggering of OX-40 (CD134) and CD4 + CD25 + T cells block their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR. Blood 105:2845-2851 (Pubitemid 40446278)
65. Piconese S, Valzasina B, Colombo MP (2008) OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection. J Exp Med 205:825-839 (Pubitemid 351549881)
66. Morel Y, Truneh A, Costello RT, Olive D (2003) LIGHT, a new TNF superfamily member, is essential for memory T helper cell-mediated activation of dendritic cells. Eur J Immunol 33:3213-3219 (Pubitemid 37428354)
67. Morel Y, Truneh A, Sweet RW, Olive D, Costello RT (2001) The TNF superfamily members LIGHT and CD154 (CD40 Ligand) costimulate induction of dendritic cell maturation and elicit specific CTL activity. J Immunol 167:2479-2486 (Pubitemid 32768873)
68. Huang J, Kerstann KW, Ahmadzadeh M, Li YF, El-Gamil M, Rosenberg SA, Robbins PF (2006) Modulation by IL-2 of CD70 and CD27 expression on CD8 T cells: importanance for the therapeutic effectiveness of cell transfer immunotherapy. J Immunol 176:7726-7735 (Pubitemid 43849073)
69. Moira Wilke C, Wu K, Zhao E, Wang G, Zou W (2010) Prognostic significance of regulatory T cells in tumor. Int J Cancer 127:748-758
70. Tosolini M, Kirilovsky A, Mlecnik B, Fredriksen T, Mauger S, Bindea G, Berger A, Bruneval P, Fridman W, Pages F, Galon J (2011) Clinical impact of different classes of infiltrating T cytotoxic and helper cells in patients with colorectal cancer. Can Res 71:1263-1271
71. Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubek-Loebenstein B (2003) Increase in regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 9:606-612 (Pubitemid 36182591)
72. Li X, Ye D, Xie X, Chen H, Lu W (2005) Proportions of CD4 + CD25 + regulatory T cells is increased in patients with ovarian cancer. Cancer Invest 23:399-403 (Pubitemid 41324357)
73. Merlo A, Casalini P, Carcangui ML, Malventano C, Triulzi T, Menard S, Tagliabue E, Balsari A (2009) FoxP3 expression and overall survival in breast cancer. J Clin Oncol 27:1746-1752
74. Loddenkemper C, Schernus M, Noutsias M, Stein H, Thiel E, Nagorsen D (2006) In situ analysis of FoxP3 regulatory T cells in human colorectal cancer. J Transl Med 4:52-59
75. Salama P, Phillips M, Grieu F, Morris M, Zeps N, Joseph D, Platell C, Iacopetta B (2009) Tumor infiltrating FoxP3 + T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol 27:186-192
76. Erdman SE, Sohn JJ, Roa VP, Nambiar PR, Ge Z, Fox JG, Schauer DB (2005) CD4 + CD25 + regulatory lymphocytes induce regression of intestinal tumors in ApcMin/+ mice. Can Res Priority Report 65:3998-4004 (Pubitemid 40775635)
77. Grivennikov SL, Greten FR, Karin M (2010) Immunity, inflammation and cancer. Cell 140:883-899
78. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, Robbins PF, Huang J, Citrin DE, Leitman SF, Wunderlich J, Restifo NP, Thomasian A, Downey SG, Smith FO, Klapper J, Morton K, Laurencot C, White DE, Rosenberg SA (2008) Adoptive cell therapy for patients with metastatic melanoma: evaluation of intense myeloablative chemoradiation preparative regimens. J Clin Oncol 26:5233-5239
79. Berger C, Turtle CJ, Jensen MC, Riddell SR (2009) Adoptive transfer of virus-specific and tumor specific T cell immunity. Curr Opin Immunol 21:224-232